XZB-0004 is under clinical development by SignalChem Lifesciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how XZB-0004’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

XZB-0004 overview

SLC-391 is under development for the treatment of solid tumors, non-small cell lung cancer (NSCLC), acute myelocytic leukemia (AML), colorectal cancer, coronavirus disease (COVID-19) and unspecified hematological malignancies. The drug candidate is a small molecule that acts by targeting AXL kinase. It is developed based on the KineCore technology. It is administered through oral route. The drug candidate was also under development for colon carcinoma and ovarian cancer.  SLC-391 was under development for the treatment of chronic myelocytic leukemia (CML), ovarian cancer, colon carcinoma.

SignalChem Lifesciences overview

SignalChem Lifesciences (SLC) is a biotechnology company that discovers and develops novel therapies for oncology. The company is investigating SLC-391, an orally bioavailable small molecule AXL inhibitors to treat acute myelogenous leukemia and non-small cell lung cancer; and SLC-0111, a carbonic anhydrase IX (CAIX) Inhibitor targeting pancreatic cancer. It is also evaluating additional programs targeting cancer and SARS-CoV-2 (corona virus). SLC provides drug discovery, in-vitro diagnostic development, research and development solutions. The company works in collaboration with pharmaceutical and biopharmaceutical companies to develop its products. SLC is headquartered in Richmond, British Columbia, Canada.

For a complete picture of XZB-0004’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.